Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
Online First
Web Exclusives
All Web Exclusives
Videos
Monthly Minutes
Conversations on CCA
Interview with the Innovators
Press Releases
CCA Summit
Cholangiocarcinoma Summit
Special Issues
2020 Year in Review - Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
Early Molecular Testing for Patients with CCA Crucial to Inform Treatment Choices
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 18, 2020
Genomic data analysis of publicly available data supports the high prevalence of potentially actionable mutations in patients with CCA, supporting use of personalized therapies alone or in combination with chemotherapy.
Read More
PFS to Systemic Therapy in Patients with CCA with FGFR2 Fusions or Rearrangements
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 18, 2020
Post-hoc analysis of the phase 2 FIGHT-202 study showed that second-line pemigatinib treatment resulted in a numerically longer PFS than standard systemic second-line treatment in patients with previously treated advanced/metastatic CCA.
Read More
Therapeutic Targeting of Extracellular FGFR2 Activating Deletions in Intrahepatic CCA
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 18, 2020
Extracellular domain FGFR2 in-frame deletions might be a novel genomic alteration in intrahepatic CCA with potential clinical sensitivity to FGFR inhibitors.
Read More
Futibatinib in Patients with Intrahepatic CCA Harboring FGFR2 Gene Fusions: A Phase 2 Open-Label Study (FOENIX-CCA2)
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 18, 2020
Preliminary results of the FOENIX-CCA2 study show that futibatinib may be effective and well-tolerated in patients with locally advanced or metastatic unresectable intrahepatic CCA harboring FGFR2 gene fusions following failure of prior lines of chemotherapy.
Read More
In Patients with Advanced or Metastatic Intrahepatic CCA and FGFR2 Fusions, Futibatinib Is Safe and Effective
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 18, 2020
Results of the global phase 2 FOENIX-CCA2 trial support the efficacy and safety of futibatinib treatment in patients with locally advanced or metastatic unresectable intrahepatic CCA and FGFR2 fusions or rearrangements, and indicate that futibatinib does not adversely affect patients’ quality of life.
Read More
Capecitabine and Cisplatin as Second-Line Chemotherapy for Patients with Advanced Biliary Tract Cancer
Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
— December 18, 2020
Retrospective analysis data suggest that second-line chemotherapy of capecitabine and cisplatin combination therapy was associated with modest efficacy in patients with advanced biliary tract cancer.
Read More
A Comprehensive Genomic Profiling Study Comparing Primary Tumor, Metastatic Tumor Tissue, and Liquid Biopsy in Patients with Intrahepatic CCA
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 18, 2020
Results of a comprehensive genomic profiling study indicate differences in genomic alterations detected from primary tumor, metastatic tumor tissue, and liquid biopsy in patients with intrahepatic CCA; IDH1 and FGFR2 genomic alterations are detectable in liquid biopsy, with potential practice-changing implications in clinical practice.
Read More
Modified FOLFOX versus Modified FOLFIRI in Patients with Locally Advanced or Metastatic Biliary Tract Cancer Refractory to First-Line Chemotherapy: A Phase 2 Study
Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
— December 18, 2020
Results of a phase 2 study indicate that mFOLFIRI was not superior to mFOLFOX in the second-line treatment of patients with biliary tract cancer.
Read More
Phase 3 ClarIDHy Study: Pharmacokinetics and Pharmacodynamics of Ivosidenib in Patients with Mutant IDH1 Advanced CCA
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 18, 2020
Results of the PK/PD analysis of the ClarIDHy study showed that the study dose of the IDH1 inhibitor ivosidenib resulted in good exposure and inhibition of oncometabolite D-2-HG.
Read More
In Patients with Advanced or Metastatic CCA and FGFR2 Fusions, Retrospective Analysis of Post–Second-Line Chemotherapy Outcomes
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 18, 2020
Results of the retrospective analysis of phase 2 study of the FGFR1-3 selective tyrosine kinase inhibitor infigratinib indicate that efficacy outcomes in patients with CCA and FGFR2 fusions were better with third- or later-line infigratinib therapy compared with standard second-line chemotherapy.
Read More
Page 3 of 4
1
2
3
4
View the Latest Issue of CCA News
Read Issue
Home
Issues
Latest Issue
Issue Archive
Special Issues
Online First
Web Exclusives
All Web Exclusives
Videos
Monthly Minutes
Conversations on CCA
Interview with the Innovators
Press Releases
CCA Summit
Cholangiocarcinoma Summit
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
CCA News
Print Edition
CCA News
Weekly e‑Newsletter
-- Please Select Country --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
CCA News
's
Privacy Policy
, and
CCA News
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION